Is plasma cell dyscrasias curable?

Multiple myeloma (MM) is an incurable plasma cell dyscrasia and the second most frequent hematologic malignancy, with an incidence of 5.85/100,000 adults in Western countries and a 5-year survival rate of 48.5% [1].

How is plasma cell dyscrasia diagnosed?

Which tests are available to monitor plasma cell dyscrasias? Quantitative monoclonal protein tests are used to monitor response to therapy and disease progression. Quantitative tests include serum protein electrophoresis (SPEP), serum free light chain (SFLC), and urine protein electrophoresis (UPEP)​ measurements.

What is the treatment of plasma cell disorder?

Treatment of extramedullary plasmacytoma may include the following: Radiation therapy to the tumor and nearby lymph nodes. Surgery, usually followed by radiation therapy. Watchful waiting after initial treatment, followed by radiation therapy, surgery, or chemotherapy if the tumor grows or causes signs or symptoms.

What is plasma cell leukemia?

Plasma cell leukemia (PCL) is a rare, yet aggressive form of multiple myeloma characterized by high levels of plasma cells circulating in the peripheral blood that can be detected on conventional peripheral blood smear examination.

What is the survival rate of plasma cell leukemia?

The prognosis of patients with plasma cell leukemia treated with conventional therapy has been reported with median survivals of 7 to 14 months for those with primary plasma cell leukemia and 2 to 7 months for those with secondary plasma cell leukemia.

Can you cure plasma cell leukemia?

Treatment and management options Plasma cell leukemia is a very aggressive cancer. In most cases, doctors cannot cure it. But a type of stem cell transplant called autologous stem cell transplantation has improved survival rates, and in some cases, may send the cancer into remission.

What is plasma cell dyscrasia?

Plasma cell dyscrasias are a heterogenous group of disorders caused by the monoclonal proliferation of plasma cells in the bone marrow. Multiple myeloma is the most serious and prevalent plasma cell dyscrasias with a median age of onset of 60 years where symptoms result from lytic bone disease, anemia, renal failure, and immunodeficiency.

What are the renal lesions of plasma cell dyscrasias (CDs)?

The renal lesions of patients with plasma cell dyscrasias present with a variety of glomerular, tubular, and vascular lesions. Proteinaceous casts are common in all forms of chronic interstitial nephritis.

What are the indications for the testing for plasma cell dyscrasia?

The testing for plasma cell dyscrasia is indicated in the following situations: Bone pain. Recurrent infection. Anemia.

Is plasma cell dyscrasia the same as amyloidosis?

Plasma Cell Dyscrasias. Amyloidosis refers to a group of tissue deposition disorders, among which light-chain amyloidosis is a plasma cell dyscrasia. Monoclonal gammopathy of undetermined significance is an asymptomatic laboratory deviation that may evolve into one of the previously mentioned diseases.